Abstract
An oncogenic form of RHAMM (receptor for hyaluronan-mediated motility, mouse, amino acids 163–794 termed RHAMMΔ163) is a cell surface hyaluronan receptor and mitotic spindle protein that is highly expressed in aggressive human cancers. Its regulation of mitotic spindle integrity is thought to contribute to tumor progression, but the molecular mechanisms underlying this function have not previously been defined. Here, we report that intracellular RHAMMΔ163 modifies the stability of interphase and mitotic spindle microtubules through ERK1/2 activity. RHAMM−/− mouse embryonic fibroblasts exhibit strongly acetylated interphase microtubules, multi-pole mitotic spindles, aberrant chromosome segregation, and inappropriate cytokinesis during mitosis. These defects are rescued by either expression of RHAMM or mutant active MEK1. Mutational analyses show that RHAMMΔ163 binds to α- and β-tubulin protein via a carboxyl-terminal leucine zipper, but in vitro analyses indicate this interaction does not directly contribute to tubulin polymerization/stability. Co-immunoprecipitation and pulldown assays reveal complexes of RHAMMΔ163, ERK1/2-MEK1, and α- and β-tubulin and demonstrate direct binding of RHAMMΔ163 to ERK1 via a D-site motif. In vitro kinase analyses, expression of mutant RHAMMΔ163 defective in ERK1 binding in mouse embryonic fibroblasts, and blocking MEK1 activity collectively confirm that the effect of RHAMMΔ163 on interphase and mitotic spindle microtubules is mediated by ERK1/2 activity. Our results suggest a model wherein intracellular RHAMMΔ163 functions as an adaptor protein to control microtubule polymerization during interphase and mitosis as a result of localizing ERK1/2-MEK1 complexes to their tubulin-associated substrates.
Keywords: ERK, Fibroblast, Microtubules, Mitotic Spindle, Oncogene, Hyaluronan Receptor, Microtubule Dynamics, Unconventional Proteins
Introduction
The interphase microtubule network is composed of α- and β-tubulin heterodimers that form tubules, which are highly dynamic structures participating in cell morphology/polarity, signaling, migration, proliferation, and protein trafficking (1–3). The effects of microtubules depend on their dynamic nature composed of polymerization and depolymerization cycles. These are primarily controlled by post-translational modification of microtubule-stabilizing (MAPs)3 and -de-stabilizing proteins (e.g. Stathmin) (4–6). The microtubules of mitotic spindles, which also contain heterodimers of α- and β-tubulin, are particularly dynamic. This property is essential for appropriate chromosome segregation and, consequently, genomic stability (7–10). The microtubule functions that depend upon dynamic cycles of polymerization/depolymerization are increasingly targeted as a means for controlling cancer growth and spread and the progression of other diseases in which microtubules play a role. For example taxanes, which promote microtubule stability, are widely used as an adjuvant treatment for cancer (11–13). However, an understanding of the molecular mechanisms controlling microtubule turnover in cancer cells is still incomplete.
RHAMM is an oncogenic protein that has been implicated in the progression of many human cancers, including breast, acute myeloid leukemia, multiple myeloma, gastric, and prostate cancers (14–16). (RHAMM/HMMR is the human gene designation, and Rhamm is the mouse gene designation; RHAMM is used here to describe the protein product of both species.) Most studies to date suggest that RHAMM overexpression promotes tumor progression. Thus, high RHAMM expression in breast cancer is predictive of poor clinical outcome (17, 18), and polymorphisms in this gene have been linked to breast cancer susceptibility in some human populations (18, 19). SERA analyses have identified RHAMM as a tumor marker for acute myeloid leukemia, and clinical trials are ongoing to assess the use of RHAMM peptide vaccines for control of acute myeloid leukemia and multiple myeloma (20).
RHAMM expression in adult mammals is largely restricted to sites of tissue injury and to pathological processes involved in chronic inflammation and neoplasia (15, 21). RHAMM is distributed within several intracellular compartments, and it is also localized to the surface of certain normal and transformed cells (21, 22). Intracellular RHAMM proteins are found in the cell nucleus (15) on interphase microtubules (23), mitotic spindles, centrosomes (24), and within mitochondria (25). RHAMM is one of a number of proteins that can be exported to the cell surface by unconventional mechanisms (15, 26). This structurally diverse group of proteins is characterized by the lack of an identifiable signal peptide for export through the Golgi/endoplasmic reticulum.
Extracellular RHAMM promotes cell motility and invasion through sustained stimulation of the activity of MEK1/ERK1/2 kinases (resulting from its association with integral receptors such as CD44 and platelet-derived growth factor receptor and with hyaluronan (15, 22, 27)). The gene designation for MEK1 is MAP2K1; for ERK1 is MAPK3, and for ERK2 is MAPK1. MEK1, ERK1, and ERK2 are used here for protein products of these genes. The functions of intracellular RHAMM are less well understood, but its association with mitotic spindles requires a leucine zipper located in the carboxyl terminus that facilitates RHAMM/tubulin interactions. These interactions are required for Ran-driven, acentrosomal mitotic spindle pole formation in Xenopus egg extracts (15, 28, 29). Forced high expression of RHAMM results in multi-pole spindles, and this effect has been linked to genomic instability in multiple myeloma (30). The pole-stimulating function of RHAMM is restricted in human cell lines by breast cancer gene 1 (BRCA1)-BRCA1 association ring domain 1 (BARD1) complexes, which safeguard the formation of focused bipolar mitotic spindles (28). Recently, intracellular RHAMM has also been implicated in abscission during cytokinesis as a result of its association with supervillin, a member of the gelsolin family of proteins (31). The molecular mechanisms underlying these two RHAMM functions in the cell cycle has not, to our knowledge, previously been reported.
Full-length RHAMM (RHAMMFL) is expressed in cultured cells and contains two microtubule-binding regions (23, 29). Injured, subconfluent, or neoplastic cultured cells express additional RHAMM protein isoforms resulting from alternative splicing and/or post-translational processing (32, 33). Most of these are amino-terminal truncations of the full-length protein and therefore contain only the carboxyl-terminal tubulin binding sequence (27). At least one of the truncated forms (e.g. RHAMMΔ163) is transforming when overexpressed in 10T1/2 MEF cell lines (32). Therefore, understanding the mechanisms by which RHAMM affects microtubule structures via its carboxyl-terminal sequence may help to clarify its role(s) in neoplastic diseases.
We have shown that intracellular RHAMM proteins, in particular RHAMMΔ163, complex with MEK1 and ERK1/2 (33). We were prompted to investigate whether or not intracellular RHAMM protein controls interphase and mitotic microtubule stability/integrity through MEK1/ERK1/2 because we reported that ERK1/2 activity is necessary for dynamic instability of interphase microtubules in RAS-transformed fibroblasts (34), and others have shown that microtubule stability results in multi-pole spindles (35), and BRCA1-ERK1/2 form complexes during mitosis (36, 37). Here, our results suggest that MEK1-ERK1/2 complexes mediate the effects of intracellular RHAMMΔ163 on interphase and mitotic spindle structure and that RHAMM performs scaffolding functions to control both activity and targeting of MEK1-ERK1/2 complexes to tubulin.
EXPERIMENTAL PROCEDURES
Reagents
α- and β-tubulin heterodimers and MAP-enriched tubulin were purchased from Cytoskeleton Inc. (Denver, CO). Mouse anti-tubulin monoclonal antibodies and anti-phospho-ERK1/2 antibodies were purchased from Sigma and Santa Cruz Biotechnology (Santa Cruz, CA). An anti-pan-ERK1/2 polyclonal antibody was purchased from BD Transduction Laboratories. Alexa dye secondary antibodies were obtained from Invitrogen. Nocodazole and the MEK1 inhibitor (PD98059) were purchased from Sigma. The mutant active MEK1 expression vector was the kind gift of Natalie Ahn (University of Colorado, Boulder). Polyclonal anti-RHAMM antibodies were prepared against the peptide sequence (mouse RHAMM) 727KLKDENSQLKSEVS740 by ProSci (Poway, CA). Additional peptides, 715HQNLKQKIKHVVKLKDENSQLKSEVSKLRSQ745 and 728LKDENSQLKSEVSKL742, which contains the leucine zipper required for an association of RHAMM with the mitotic spindle (28), and control peptides 195KLQATQKDLTESKGKLVQLEGKL217 and control peptide 2 (218VSIEKEKIDEK228) were used in MAPK binding assays and were synthesized at the London Regional Cancer Program Proteomics Center. Biotinylated hyaluronan was purchased from Hyalose (Oklahoma City, OK).
Cells and Cell Lines
10T1/2 and C3 10T1/2 fibroblasts were purchased from ATCC (Manassas, VA). 10T1/2 fibroblasts were transfected with RHAMM cDNA constructs shown in Fig. 1A as described previously (32). Constructs contained either an HA or Myc epitope tag (32, 33). RHAMM−/−, RHAMMFL-rescued, RHAMMΔ163-rescued, and mutant active MEK1-rescued MEF cell lines were prepared as described previously (33). Primary mouse embryonic fibroblasts with genotypes RHAMM−/− and RHAMM+/+ (wild type) were obtained from RHAMM+/− heterozygote matings and were thus litter-matched. MEFs were isolated from ED14 mouse embryos as described previously (34).
FIGURE 1.
RHAMM is expressed by primary and immortalized MEF. A, diagram of RHAMM transcripts expressed by 10T1/2 cells. RHAMMFL contains two microtubule-binding sequences; one is located in exon 4 and the other in exon 16 (arrows). The latter contains a leucine zipper responsible for the association of RHAMM with mitotic spindles (29). An amino-terminal truncation of RHAMM (RHAMMΔ163) contains only the mitotic spindle binding sequence, yet retains the ability to bind to interphase microtubules. aa, amino acid. B, left panel, RHAMM protein expression of 10T1/2 cells and 10T1/2 cells transfected with RHAMMΔ163. An anti-RHAMM polyclonal antibody recognizing sequences in exon 8 was used to detect RHAMM by Western analysis. Arrows indicate RHAMMFL and RHAMMΔ163. Right panel, RHAMM mRNA expression of wild type, RHAMMΔ163-transfected RHAMM−/−, RHAMMFL-transfected RHAMM−/−, and RHAMM−/− MEF. Quantitative real time PCR using primers common to both RHAMMΔ163 and RHAMMFL was employed to quantify mRNA expression. RHAMM−/− MEF do not express RHAMM mRNA. Transfection of RHAMM−/− cells with RHAMMΔ163 or RHAMMFL restores RHAMM mRNA expression. C, RHAMM protein expression of RHAMM−/−, RHAMMFL, and RHAMMΔ163 MEF was detected by immunofluorescence using RHAMM exon 8-specific polyclonal antibodies. As expected, RHAMM−/− MEF do not express RHAMM protein, whereas RHAMMΔ163 and RHAMMFL rescued RHAMM−/− MEF do. Images were taken with a Zeiss confocal microscope at ×40 magnification. Laser settings were kept constant.
Immunofluorescence
Cells were plated overnight on sterile glass coverslips at 50% subconfluence in DMEM supplemented with 10% FBS. Cells were fixed with buffered 3% paraformaldehyde and then permeabilized with 0.1% Triton X-100 in PBS. Nonspecific binding sites were blocked with 3% BSA in PBS for 1 h at 20 °C. Anti-tubulin, anti-acetylated tubulin, and anti-phospho-ERK1/2 antibodies were diluted 1:100; anti-RHAMM antibodies were diluted 1:1000. Fixed cultures were incubated with primary antibodies for 2 h at 20 °C. Cultures were washed in 3% BSA in PBS and then incubated with Alexa dye-labeled secondary antibodies, which were diluted 1:150. Cultures were washed again in 3% BSA/PBS and then mounted in a Vectashield mountant containing DAPI (1.5 μg/ml).
Western and Far Western Blots
Cell lysates were prepared using RIPA buffer as described previously (33). Equal amounts of cell lysate or GST-RHAMM recombinant protein were resolved by electrophoresis on a 10% SDS-polyacrylamide gel. Separated proteins were transferred to nitrocellulose membranes in a buffer containing 25 mm Tris-HCl, pH 8.3, 192 mm glycine, and 20% methanol using electrophoretic transfer cells (Bio-Rad) at 100 V for 1.5 h at 4 °C. Membranes were incubated in TBST + 5% defatted milk to block nonspecific protein-binding sites, and then the membranes were incubated with primary antibodies at dilutions recommended by the manufacturer for 2 h at 4 °C. Polyclonal anti-RHAMM antibodies were used at a dilution of 1:15,000. Membranes were washed, and immunodetection was then performed using secondary antibodies provided in an ECL kit (Invitrogen).
For far-Western analyses, recombinant GST-RHAMM was separated on SDS-PAGE and transferred to nitrocellulose membranes as above. Microtubule protein (Cytoskeleton Inc., 99% α- and β-tubulin heterodimers) was incubated with the nitrocellulose membrane at 0.2 μg/ml as described for primary antibodies, washed, and then incubated with an anti-α-tubulin mouse monoclonal antibody (1:100 dilution). Bound tubulin antibodies were detected using goat anti-mouse-HRP secondary antibody. Bound antibody was detected with reagents in an ECL kit as above.
Pulldown Assays
Recombinant mouse GST-RHAMM proteins and GST protein by itself were produced in bacteria as described previously (22) and then subsequently purified using glutathione-Sepharose 4B beads (GE Healthcare). ERK1, ERK2, and MEK1 recombinant proteins (human) were purchased from Enzo Life Sciences, Inc. (Plymouth Meeting, PA). Based on a Coomassie Blue-stained SDS-polyacrylamide gel, 100 μl of GST-RHAMM(706–767) beads and 50 μl of GST beads were used for this assay. The beads were washed with 1× PBS before blocking with 100 mm lactose overnight at 4 °C. Purified bovine α- and β-heterodimeric tubulin (Cytoskeleton Inc.) was diluted in tubulin buffer to a concentration of 50 μg/ml, and 500 μl was mixed with lactose-blocked GST-RHAMM(706–767) or GST beads alone at 4 °C for 3 h. The beads were then washed with 1 ml of wash buffer (50 mm Tris, pH 8.0, with 0.1% Triton X-100) five times at 4 °C. 100 μl of 2× SDS loading buffer was added to beads, which were boiled at 95 °C for 10 min, and then 20 μl of the supernatant were loaded on a 10% SDS-polyacrylamide gel. Separated proteins were transferred to a nitrocellulose membrane and incubated with anti-tubulin antibodies as described above for Western blots. To confirm binding of α- and β-tubulin to RHAMM in cells, cell lysates were prepared from primary RHAMM−/− and wild type MEF as described above, and then pulldown assays were performed using recombinant RHAMM(706–767) linked to Sepharose beads. Beads were washed, and associated proteins were separated on a gradient SDS-PAGE (5–12%) and lightly stained with silver, and clearly separated bands in the range of 45–65 kDa were cut out, protein-eluted, and identified with MALDI-TOF analysis (Emili and Greenblatt Proteomics Research Center, University of Toronto, Toronto, Canada).
To assess direct binding of RHAMM to ERK1, ERK2, and MEK1, purified GST-RHAMM recombinant protein (mouse, amino acids 164–794) was immobilized on glutathione-Sepharose as a GST fusion protein or covalently linked to SulfoLink gel as per the manufacturer's instructions (Pierce). Recombinant MAPKs were incubated with GST-RHAMM beads in binding buffer (25 mm HEPES, pH 7.2, 50 mm NaCl; 10 mm MgCl2) for 1 h at 4 °C on a nutator. Beads were sedimented by centrifugation, washed 10 times with 1 ml of cold binding buffer/wash, then boiled in SDS-PAGE loading buffer before electrophoresis on 10% SDS-PAGE, and transferred to a nitrocellulose membrane for Western blot analysis. For competition analyses, 1 μg of MAPK recombinant protein was incubated with 10 μg of peptide or soluble recombinant wild type or mutant RHAMM protein at 4 °C on a nutator for 1 h, and GST-RHAMM beads were then added, and the mixture was incubated an additional 1 h. GST-RHAMM beads were captured by centrifugation and analyzed as above for bound MAPKs.
Microtubule Pelleting Assays
Pelleting assays were performed using GST-RHAMMΔ373 and GST-RHAMMΔ163 recombinant proteins or GST alone used as a control. These proteins were incubated with taxol-stabilized porcine microtubules, prepared according to manufacturer's instructions (MAP spin-down assay kit, Cytoskeleton Inc.). 1–2 μg/ml recombinant RHAMM proteins were dissolved in microtubule cushion buffer (PEM) supplemented with 2 mm DTT and 20 μm taxol. The solution was pre-cleared by centrifugation at 80,000 × g for 45 min at 4 °C. The supernatant was decanted and incubated with either 50 μm of taxol-polymerized microtubules or buffer alone. Samples were layered over 350 μl of 10% glycerol in PEM, and microtubules were sedimented from soluble protein by centrifugation at 80,000 × g for 40 min at room temperature. Equal amounts of the supernatant and pellet were separated on 10% SDS-polyacrylamide gels, and tubulin was detected by Western blot analysis as described above.
Immunoprecipitation Assays
Immunoprecipitations were performed using 500 μg of protein from cell lysates pre-cleared with 10 μl of protein A/G-Sepharose beads (Invitrogen). The pre-cleared lysate was incubated with primary antibodies for 12 h at 4 °C on a nutator at concentrations recommended by the manufacturer. Anti-RHAMM polyclonal antibodies were used at 5/400 μg of cell lysate. The protein-antibody complexes were captured with protein A/G-Sepharose beads, which were pelleted and washed. Bound protein was released by boiling in 25 μl of Laemmli buffer. Released proteins were separated on a 10% SDS-PAGE as described above, and Western blots were conducted as described above.
Analysis of Acetylated Tubulin Levels in Soluble and Insoluble Fractions
1 × 105 cells were plated on fibronectin-coated (10 μg/ml) cell culture dishes in DMEM, 10% FCS containing antibiotics/antimycotics. 24 h later, cells were washed with PBS. The soluble fraction was isolated by treating cells with 300 μl of microtubule stabilizing buffer (0.1 m Pipes, pH 6.9, 1 mm EGTA, 2.5 mm GTP, 4% PEG 6000, 0.2% Triton X-100) plus proteinase and phosphatase inhibitor on ice. Following removal of the soluble fraction, the insoluble fraction was isolated by treating cells with 300 μl of RIPA lysis buffer (50 mm Tris-HCl, pH 7.4, 150 mm NaCl, 2 mm EDTA, 1% Nonidet P-40, 0.1% SDS) on ice and scraping the plate with a cell scraper. Soluble and insoluble fractions were stored at 4 °C (short term) or −80 °C (long term) prior to quantifying the protein concentration using an Advanced Protein Assay (Cytoskeleton, Inc.). Equal amounts of protein were loaded on an SDS-polyacrylamide gel and separated by electrophoresis as described above. Western analyses were performed using 1:1000 anti-acetylated and 1:1000 total (α and β) tubulin antibodies (Sigma).
Resistance of Interphase Microtubules to Nocodazole
Cells were plated at 50% confluence on fibronectin-coated coverslips as above. 24 h later, cells were treated with culture medium containing different concentrations of either nocodazole or DMSO for 30 min. After treatment, cells were washed with PBS and incubated with microtubule stabilizing buffer for 10 min on ice. Cell monolayers were washed again with PBS and then fixed in 4% paraformaldehyde in PBS for 10 min on ice. After fixation, cells were washed for 5 min with PBS and then blocked with 3% BSA/PBS for 1 h at room temperature. Cells were incubated overnight at 4 °C with either 1:200 diluted (1% BSA/PBS) anti-α-tubulin antibody or isotype-matched nonimmune IgG (Cytoskeleton Inc.). Monolayers were washed three times at 5-min intervals with PBS followed by 30 min of incubation with 1:200 diluted (1% BSA/PBS) secondary anti-mouse or anti-rabbit secondary antibody (labeled with Alexa Fluor 647). Monolayers were washed three times at 5-min intervals with PBS to remove unbound secondary antibody and then incubated with a 1:20,000 dilution (PBS) of DAPI for 10 min to detect nuclei. Monolayers were washed three times in PBS at 5-min intervals and then mounted in Dako fluorescent mounting medium and examined with an Olympus confocal microscope.
Nocodazole-induced Cell Cycle Block
Cells were plated at 50% confluence on sterile coverslips in DMEM, 10% FCS plus antibiotic/anti-mycotic, incubated at 37 °C, 5% CO2 humidified atmosphere, allowed to adhere for 5–6 h, and then incubated for 24 h in 60 ng/ml of nocodazole. Cells were released from the nocodazole block by washing monolayers three times with DMEM + 10% FCS. Monolayers were fixed in 3% paraformaldehyde at 2, 4, and 6 h following the removal of nocodazole and were stained for α-tubulin using anti-tubulin antibodies as described above. Cells were photographed with an Olympus confocal microscope.
Quantitative PCR
RNA was isolated from 50% confluent cells using TRIzol (Invitrogen) following the manufacturer's instructions. 1 μg of RNA was reverse-transcribed using SuperScriptII (Invitrogen) following the manufacturer's instructions. Oligo(dT) (Invitrogen) was used as primer for cDNA synthesis. CYBR Green PCR master mix was purchased from SA Biosciences (Frederick, MD). PCR amplification was performed on a Stratagene MX 3000 instrument. The primer sequences are as follows: RHAMM left primer, GGAAGCAGCTGGAAGAGAAA; RHAMM right primer, CTGTTTCTCGGCTTCAAAGG; β-actin left primer, CTCTTTGATGTCACGCACGATTTC; β-actin right primer, GTGGGCCGCTCTAGGCACCAA. The cycle conditions were as follows: 10 min at 94 °C, 30 s at 94 °C, 45 s at 55 °C, 45 s at 77 °C, and 10 min 72 °C. Relative expression levels were calculated as ΔCt. Amplification of β-actin was used for standardization.
RESULTS
RHAMMΔ163 Decorates Both Interphase and Mitotic Spindle Microtubules
RHAMMFL was previously shown to decorate both interphase and mitotic spindles of epithelial and immune cells (23, 30). We wanted to confirm the co-localization of RHAMM proteins with microtubule structures in 10T1/2 fibroblasts, which express both endogenous RHAMMFL and truncated RHAMM forms, including small amounts of RHAMMΔ163 (Fig. 1, A and B). In the mouse, these RHAMM proteins are 95 and 70 kDa, respectively. As noted previously for the other cell types (23, 29), these endogenous RHAMM proteins decorated the poles of mitotic spindles in 10T1/2 fibroblasts as well as the length of interphase microtubules (Fig. 2A). Primary wild type MEF expressed lower levels of RHAMM protein than 10T1/2 fibroblasts, and expression was most easily detected in these primary cells by mRNA analysis (Fig. 1B, graph). Analysis showed that the predominant RHAMM protein was full length. Therefore, immortalized RHAMM−/− MEF lines (22) were transfected with either RHAMMFL or RHAMMΔ163 to compare the tubulin binding properties of both RHAMM protein forms. Expression of these two RHAMM forms in transfected cells was confirmed with quantitative PCR and immunohistochemistry (Fig. 1, B, graph, and C). When photographed at the same laser intensity, primary RHAMM−/− MEF as well as immortalized RHAMM−/− MEF lines exhibited large bundles of brightly staining interphase microtubules in contrast to the interphase microtubules of either immortalized RHAMM-rescued lines or primary wild type MEF, which stained less brightly (Fig. 2B). Primary and immortalized RHAMM−/− MEF exhibited a high frequency of multi-pole mitotic spindles (Fig. 2B and supplemental Fig. 1A) and chromosome misalignment on these aberrant spindles. Expression of RHAMMFL rescued both interphase microtubule abnormalities and mitotic spindle/chromosome segregation defects (Fig. 2B). These results suggested that, in addition to decorating microtubule structures, RHAMM plays an essential and nonredundant role in microtubule integrity.
FIGURE 2.
RHAMM decorates microtubules and its expression affects microtubule structures. A, RHAMM decorates interphase microtubules and mitotic spindles. Immunofluorescence staining with anti-RHAMM exon 8-specific polyclonal antibodies was used to analyze RHAMM expression and distribution in 10T1/2 cells. Tubulin was detected by staining with an anti-α-tubulin antibody. RHAMM co-distributes with tubulin in interphase microtubules of 10T1/2 fibroblasts. RHAMM also co-localizes with tubulin in mitotic spindle microtubules (lower three panels) of 10T1/2 cells and is particularly concentrated at the spindle apex. Images were taken on a Zeiss confocal microscope. B, immunofluorescence staining of RHAMM−/−, RHAMMFL-rescued and wild type MEF shows that microtubules stain more brightly in RHAMM−/− MEF than in either RHAMM-rescued or wild type MEF (images were taken at the same laser setting). Small inset in image of RHAMM-rescued MEF shows tubulin staining taken at higher laser setting. Nuclei of RHAMM−/− MEF are often larger and cells more highly spread than RHAMM-rescued cells. RHAMM loss also results in aberrant mitotic spindle formation and defective chromosome alignment/segregation compared with RHAMM-rescued or wild type MEFs. Arrows indicate poles of mitotic spindles. Images were taken with an Olympus confocal microscope at ×40 magnification.
RHAMM Associates with Both Interphase and Mitotic Spindle Microtubules
Previous studies identified microtubule-binding sequences in both exon 4 and 16 of RHAMMFL (Fig. 1A) (23, 29). In these studies, deletion of amino acids 1–103 resulted in loss of RHAMM on interphase microtubules and its accumulation in the nucleus (23). An additional microtubule-binding site was identified in the carboxyl terminus of RHAMM that co-immunoprecipitated with γ-tubulin (29) and mediated an association with centrosomes and mitotic spindles (24, 29). This second binding site contained a leucine zipper (mouse, 728LKDENSQLKSEVSKL742), which was required for decoration of RHAMM on mitotic spindles (28, 29). These collective results were interpreted as evidence that the two tubulin-binding sequences of RHAMMFL performed separate functions; the amino-terminal sequence was proposed to regulate interphase microtubules, and the carboxyl-terminal sequence was proposed to regulate mitotic spindle/centrosome integrity.
To confirm this separation of tubulin-binding sites, we first prepared Myc-tagged amino-terminal truncations of RHAMMFL that lacked the tubulin-binding site in exon 4 (e.g. RHAMMΔ373, Fig. 3A, and RHAMMΔ163, data not shown). These constructs were expressed in 10T1/2 fibroblasts, and their ability to decorate interphase and mitotic spindle microtubules was assessed with immunofluorescence assays (Fig. 3A, interphase microtubules shown). Results unexpectedly showed that the carboxyl-terminal tubulin-binding region alone was sufficient to locate RHAMM to both interphase and mitotic spindle microtubules. The Myc tag did not modify the association of RHAMM with microtubules because untagged truncated RHAMM cDNAs expressed in RHAMM−/− MEF also decorated interphase microtubules (data not shown). These results predicted that the leucine zipper bound to both interphase and spindle microtubules, raising the possibility that short RHAMM forms such as RHAMMΔ163 affect interphase and mitotic spindle microtubules by a common mechanism.
FIGURE 3.
Myc-RHAMMΔ373 binds to interphase microtubules, and loss of RHAMM expression increases interphase microtubule resistance to nocodazole. A, 10T1/2 cells were transfected with a RHAMM expression construct lacking the first amino-terminal 373 amino acids (aa) (RHAMMΔ373). To distinguish between expression of the transfected construct from endogenous RHAMM, RHAMMΔ373 included an amino-terminal Myc epitope tag. RHAMMΔ373-transfected 10T1/2 cells were stained with Myc tag (green) and anti-α-tubulin (red) antibodies. RHAMMΔ373 and α- tubulin co-localize on interphase microtubules (yellow). Images were taken with a Zeiss confocal at ×40 magnification. B, nocodazole resistance of interphase microtubules is increased in RHAMM−/− MEF. Primary wild type and RHAMM−/− MEF were exposed to 3 ng/ml nocodazole or buffer containing DMSO alone. Soluble and insoluble protein fractions were isolated and separated on a 10% SDS-polyacrylamide gel. The amount of α-tubulin in both fractions was quantified by Western analysis using an α-tubulin antibody. Values represent the mean ± S.E. of n = 6 samples Statistical significance was assessed by a Student's t test, and significant results (p < 0.01) are marked by asterisks.
RHAMMΔ163 Promotes Microtubule Instability
Because loss of RHAMM expression resulted in the appearance of brightly staining, large microtubule networks (e.g. Fig. 2B), we assessed the possibility that RHAMM expression affects microtubule stability. Stability was compared in primary RHAMM−/− and wild type MEF by quantifying resistance of interphase microtubules to disruption by nocodazole and by measuring α-tubulin acetylation levels, the latter used as a marker for stable microtubules. Interphase microtubules of primary RHAMM−/− MEF were more resistant to disruption by nocodazole than wild type MEF (Fig. 3B and supplemental Fig. 2). α-Tubulin was also significantly more acetylated in primary and immortalized RHAMM−/− MEF compared with immortalized RHAMM-rescued MEF (Fig. 4A) and primary wild type MEF (Fig. 4B). The expression of RHAMM containing either one (RHAMMΔ163) or two (RHAMMFL) microtubule-binding sites rescued this RHAMM−/− microtubule phenotype equally well (Fig. 4, A and B), predicting that the carboxyl-terminal mitotic spindle/tubulin-binding site was able to mediate interphase microtubule interactions.
FIGURE 4.
Stability of interphase microtubules is modified by RHAMM expression and by activated MEK1. A, acetylated and total tubulin levels in 50% confluent RHAMM−/−, RHAMMΔ163-rescued, and RHAMMMEK1-rescued MEF were detected by Western analysis using anti-α-acetylated tubulin and α-tubulin antibodies. Graph shows the ratio of acetylated tubulin to total tubulin. B, comparison of microtubule stability between primary RHAMM−/− and wild type MEF. 50% confluent wild type and RHAMM−/− MEF were serum-starved overnight in defined medium. 30 min after stimulation with 10% FBS, total protein was isolated, and levels of acetylated and total α-tubulin levels were determined by Western analysis. Values in both A and B are the mean ± S.E. of n = 3 replicates. Statistical significance was assessed by a Student's t test, and significant results (p < 0.01) are marked by asterisks.
Spindle microtubules resemble their interphase counterparts in that they are dynamically regulated, at least in part, by similar mechanisms. To further characterize the mitotic functions of RHAMMΔ163 and to assess if RHAMM expression affected mitotic spindle stability, we quantified mitotic processes that reflect the dynamic nature of mitotic microtubules such as spindle integrity (10, 35, 36), chromosome segregation (37), and abscission during cytokinesis (38) in immortalized RHAMM−/−, RHAMMΔ163, and RHAMMFL-rescued MEF (Figs. 5 and 6 and supplemental Fig. 3). The occurrence of bi-pole versus multi-pole spindles and abnormal chromosome alignment on the mitotic spindle were used as indicators of aberrant spindle formation (35). Abnormal cytokinesis was detected by time-lapse analysis of mitotic cells (31) and by the presence of multinucleated cells.
FIGURE 5.
RHAMM loss results in aberrant mitotic spindles. Genetic loss of RHAMM results in a high percentage of multi-pole mitotic spindles and aberrant chromosome alignment. Arrows denote spindle poles, and arrowheads denote chromosomes. Cells were treated with nocodazole overnight to increase the number of cells undergoing mitosis. 2 h after nocodazole removal, cells were fixed and stained with α-tubulin antibody and DAPI. Expression of RHAMMFL or mutant active MEK1 significantly reduces the number of multi-pole spindles. RHAMMFL restores chromosome alignment on mitotic spindles to a greater degree than mutant active MEK1. Images were taken with an Olympus confocal microscope at 40× magnification and 1.6× zoom. Graph depicts percentage of cells with two, three, or more than three spindle poles. Values in the graph are the mean ± S.E. of n = 150 cells. Statistical significance was assessed by a Student's t test. Significant results (p < 0.01) are marked by asterisks.
FIGURE 6.
RHAMM loss results in increased multinucleated cells. RHAMM−/− MEF exhibit a higher percentage of multinucleated cells than RHAMMΔ163, RHAMMFL, or activated MEK1-rescued MEF. Expression of either RHAMMFL or RHAMMΔ163 were rescued to a similar extent as mutant-active MEK1. Cells were cultured overnight, and 50% confluent cultures were fixed, and nuclei were stained with DAPI. Cells with single and multiple nuclei were counted per microscopic field. Graph depicts percentage of cells with multiple nuclei. Values are the mean ± S.E. of n = 160 cells pooled from two separate experiments. Statistical significance was assessed by a Student's t test, and significant results (p < 0.01) are marked by asterisks.
Immortalized RHAMM−/− MEF exhibited a high percentage (almost 40% of mitotic cells) of multi-pole spindles, and this defect was most strongly reduced by the expression of RHAMMFL (Fig. 5) and, interestingly, to a lesser extent by expression of RHAMMΔ163 (data not shown). Chromosome segregation was aberrant on multiple pole spindles, and this defect was also rescued by expression of RHAMMFL (e.g. Fig. 5). A similar finding was observed when primary RHAMM−/− MEF were compared with primary wild type MEF (supplemental Fig. 1B). Large multinucleated cells were common in RHAMM−/− MEF populations, and their presence was reduced by either RHAMMFL or RHAMMΔ163 expression (Fig. 6 and supplemental Fig. 3B). Time-lapse analysis of RHAMM−/− MEF revealed a high percentage of cells with aberrant abscission during cytokinesis (supplemental Fig. 3). Abscission defects ranged from failure of the cleavage furrow to form in mitotic cells, resulting in giant multinuclear cells, to formation of multiple cleavage furrows, resulting in many small daughter cells, most of which lacked nuclei. These defects were equally rescued by the expression of RHAMMFL or RHAMMΔ163. Collectively, data suggested that RHAMM was required for regulating stability of interphase and mitotic microtubules and that this function resided in the carboxyl-terminal 728LKDENSQLKSEVSKL742 microtubule-binding site.
RHAMM Directly Binds to α- and β-Tubulin
To begin to identify the mechanisms by which the carboxyl terminus of RHAMM affected interphase and mitotic spindles, we identified binding partners for 728LKDENSQLKSEVSKL742. We first determined that recombinant RHAMM fragments containing this sequence (supplemental Fig. 4A) bound equally well to both soluble tubulin and pelleted, taxol-stabilized microtubules (supplemental Fig. 4B). We subsequently used soluble tubulin extracts for our assays. α- and β-tubulins are common to both mitotic spindle and interphase microtubules, whereas γ-tubulin is uniquely present in centrosomes and mitotic spindles (5, 6). We therefore first performed pulldown assays using recombinant carboxyl-terminal RHAMM fragments (supplemental Fig. 4A) and 10T1/2 fibroblast lysates. MALDI-TOF analysis was performed on isolated proteins that were separated on SDS-PAGE. Analysis showed that RHAMMΔ163 bound to α- and β-tubulin (data not shown). γ-Tubulin was not detected in these assays, although this may have been due to limiting amounts in 10T1/2 cell lysates relative to the other tubulin isoforms. To assess if interactions were direct or indirect, pulldown assays were performed using purified α- and β-tubulin heterodimers and a recombinant RHAMM(706–767) fragment linked to Sepharose beads (Fig. 7A). Bound proteins were separated on SDS-PAGE and identified using anti-α or β-tubulin antibodies with Western blots. Sepharose-GST served as a negative control. RHAMM(706–767) bound to tubulin heterodimers (Fig. 7A), whereas GST alone did not. The ability of truncated RHAMM forms that are represented in cells (e.g. RHAMMΔ163 and RHAMMΔ373) to bind directly to these tubulin isoforms was confirmed with a far-Western assay using soluble α- and β-tubulin heterodimers as probes (supplemental Fig. 4C). The laddering of recombinant RHAMM proteins in the assay shown in supplemental Fig. 4C was due to protease activity. The interaction between recombinant RHAMM(706–767) and tubulin heterodimers was strongly reduced by the presence of a synthetic peptide (LKDENSQLKSEVSKL) mimicking the RHAMM carboxyl-terminal leucine zipper (Fig. 7B). Collectively, these results indicated that the interaction between the carboxyl-terminal binding site in RHAMM and tubulin was direct and mediated by the highly conserved mitotic spindle binding 728LKDENSQLKSEVSKL742 sequence (28, 29).
FIGURE 7.
RHAMM binds directly to heterodimeric α-, β-tubulin. A, pulldown assays were performed using Sepharose-GST-RHAMM(706–767) and purified α-, β-tubulin heterodimers. Tubulin that bound to RHAMM was identified with Western blots using an anti-pan-tubulin antibody. IB, immunoblot. B, binding of GST-RHAMM(706–767) to tubulin heterodimers is blocked by a synthetic peptide mimicking the leucine zipper (mouse, Leu728–Leu742), which is required for an association of RHAMM with the mitotic spindle. Pulldown assays using Sepharose-GST-RHAMM(706–767) and tubulin heterodimers were performed in the presence of varying amounts of synthetic peptide. Values in the graph are the mean ± S.E. of n = 3 separate experiments. Asterisks denote statistical significance (Student's t test, p < 0.01).
MEK1/ERK1/2 Mediate the Effects of RHAMM on Interphase and Mitotic Microtubules
We next investigated how RHAMMΔ163 affected microtubule stability. Previous studies had suggested RHAMMFL directly modified tubulin stability by promoting polymerization, similar to many other MAPs (23). To assess this possibility, the ability of GST-RHAMM to modify formation of taxol-stabilized tubulin polymers was assessed in vitro (supplemental Fig. 5). Recombinant RHAMMΔ163 and RHAMMΔ373 fragments did not significantly increase or decrease the amount of pelleted microtubules. These results suggested that RHAMM fragments such as RHAMMΔ163 indirectly affected microtubule stability.
We previously showed that a H-RAS/ERK1/2 pathway promoted dynamic turnover of interphase microtubules, using α-tubulin acetylation as a marker for microtubule stability (33, 34). ERK1/2 were originally isolated from microtubules, and these kinases decorate both interphase (34, 39) and mitotic spindles (28, 29, 40). Because we reported that intracellular RHAMMΔ163 complexed with MEK1/ERK1/2 kinases and was required for activation of these MAPKs through H-RAS (32, 33), we assessed the role of ERK1/2 activity in RHAMM-mediated effects on microtubule stability.
The effect of a MEK1 inhibitor, PD98059, on acetylation of α-tubulin in RHAMMΔ163-transfected and H-RAS-transformed 10T1/2 cells, both of which expressed high levels of RHAMMΔ163, was assessed. PD098059 significantly increased acetylated tubulin levels in these cell lines, although this inhibitor had little effect on parental 10T1/2 cells, which expressed low levels of RHAMMΔ163 (Fig. 1B and supplemental Fig. 6). Conversely, expression of mutant active MEK1 in immortalized RHAMM−/− MEF reduced acetylated tubulin to levels similar to RHAMMΔ163-transfected MEF, thus phenocopying the effects of RHAMMΔ163-rescue on interphase microtubules (Fig. 4).
Although a direct role for ERK1/2 in somatic cell centrosome-driven mitosis is still controversial (40–42), the above results and evidence that ERK1/2 phosphorylate protein substrates during G2/M (43) prompted us to examine the role of these kinases in RHAMM-mediated events of mitosis. Mitotic spindle integrity, chromosome segregation, and cytokinesis fidelity were compared in immortalized RHAMM−/− MEF following stable expression of either RHAMMFL or mutant active MEK1. Mutant MEK1 increased ERK1/2 activity as expected (data not shown) (22), reduced the frequency of cells with multi-pole mitotic spindles, and restored bi-pole spindles similar to that observed with RHAMM-rescue (Fig. 5). Activated MEK1 also restored the fidelity of cytokinesis in immortalized RHAMM−/− MEF to the same degree as RHAMM-rescue, as detected by time-lapse analyses and quantification of multinucleated cells (Fig. 6 and supplemental Fig. 3). However, despite promoting normal mitotic spindle morphology, activated MEK1 did not restore normal chromosome alignment and segregation on the mitotic plate to the extent of RHAMM-rescue (e.g. Fig. 5).
RHAMM Binds Directly to ERK1 and Mutation of Its ERK Docking Sequence Phenocopies RHAMM Loss
Our previous work showed that cell surface RHAMM regulated ERK1/2 activation through an association with the integral hyaluronan receptor, CD44 (22, 27). To exclude a possible involvement of cell surface RHAMM-activated ERK1/2 in controlling microtubule dynamics, we added recombinant RHAMMΔ163 beads to RHAMM−/− MEF and quantified their effect on mitosis using time-lapse analysis (22). Extracellular RHAMMΔ163 did not rescue the mitotic defects of immortalized RHAMM−/− MEF (data not shown) indicating that cell surface activation of ERK1/2 through RHAMM was not sufficient for driving alterations in microtubule dynamics. These and data described above raised the possibility that intracellular RHAMM proteins, in particular RHAMMΔ163, scaffolded MEK1/ERK1/2 to tubulin.
Protein kinase-anchoring proteins generally bind directly to their target kinase (44). We therefore determined if GST-RHAMM bound directly or indirectly to MEK1, ERK1, and ERK2 recombinant proteins using pulldown assays. Surprisingly, only ERK1 bound directly to recombinant RHAMMΔ163 (Fig. 8B) suggesting that previously noted interactions of RHAMM with MEK1 and ERK2 were indirect (e.g. Fig. 9C). Binding to ERK1 was specific in that soluble GST-RHAMM competed with ERK1/RHAMM bead interactions (Fig. 8B). Examination of the RHAMMΔ163 sequence revealed a highly conserved MAPK “D” docking site (Fig. 8A). These sites are composed of positively charged and hydrophobic clusters of amino acids separated by 2–6 amino acids and are common to many of ERK1/2 scaffolds and substrates (45). To determine whether the sequence Lys721–Leu728 acted as a docking site for ERK1, we used two experimental approaches. In the first approach, both Lys721 and Lys727 were mutated to Glu721 and Glu728, and recombinant mutant GST-RHAMM was assayed for binding to ERK1 in pulldown assays; binding was reduced by ∼50% (Fig. 8C). In the second approach, a synthetic peptide containing the putative D-site sequence (His715–Gln745, Fig. 8A) was used to compete for RHAMMΔ163/ERK1 interactions (Fig. 8B). This peptide reduced binding of ERK1 to RHAMMΔ163 by ∼90% (Fig. 8C). Unrelated synthetic RHAMM peptides (Fig. 8A) had no effect on binding (Fig. 8C) and served as controls.
FIGURE 8.
RHAMM binds directly to recombinant ERK1. A, diagram of mouse RHAMM carboxyl-terminal sequence containing the leucine zipper (boldface letters) necessary for RHAMMΔ163/tubulin interactions and an upstream, highly conserved sequence resembling a D-site for docking ERK (dashed red line). Residues that were mutated in mutant RHAMMΔ163 are indicated in red, and the sequences of the peptide used for competing ERK1/RHAMM interactions and control peptides are indicated. B, Western blots of pulldown assays using Sepharose-GST-RHAMMΔ163 beads and recombinant ERK1 demonstrate direct binding of recombinant RHAMMΔ163 to recombinant ERK1 protein. Increasing concentrations of excess, soluble recombinant RHAMMΔ163 was included in pulldown assays to block RHAMMΔ163/ERK1 binding by competition and to demonstrate specificity of binding. Similar pulldown assays were used to assess interactions of RHAMMΔ163 with MEK1 and ERK2, but binding was not detected. IB, immunoblot. C, binding region required for RHAMMΔ163/ERK1 interactions is identified by pulldown assays using mutant recombinant RHAMMΔ163 (721Lys/Glu, 727Lys/Glu) and competition with a peptide containing the wild type sequence. Mutation of two lysine residues reduces binding by ∼60%, whereas a peptide representing the entire putative docking region reduces binding by ∼90%.
FIGURE 9.
Mutation of RHAMMΔ163 D-site reduces RHAMM/ERK1 interactions and association of p-ERK1/2 with tubulin. A, native and mutant (loss of ERK docking) RHAMMΔ163 were expressed in 10T1/2 fibroblasts, and the association of RHAMM with ERK1 and MEK1 was assessed by immunoprecipitation (IP) using anti-RHAMM antibodies. Although native RHAMMΔ163 immunoprecipitates with ERK1, ERK2 (data not shown), and MEK1, mutant RHAMMΔ163 does not. Immunoprecipitations using anti-ERK1 and nonimmune IgG were used as positive and negative controls, respectively. B, H-RAS-transformed cells express high levels of endogenous RHAMMΔ163 and display abundant tubulin-associated p-ERK1/2, as detected by immunoprecipitation assays using anti α-tubulin antibodies. Expression of mutant RHAMMΔ163, which acts as a dominant negative suppressor of endogenous RHAMMΔ163 function, ablates the association of p-ERK1/2 with tubulin. Densitometry values represent the mean ± S.E. of n = 4 samples. Asterisks denote statistical significance (Student's t test, p < 0.01). C, diagram of proposed interactions among RHAMM, MEK1, ERK1/2 and tubulin. RHAMM is predicted to scaffold MEK1/ERK1/2 to tubulin in mitotic spindle and interphase microtubules. RHAMM binds directly to ERK1 through its D-site and to tubulin through its carboxyl-terminal leucine zipper but indirectly complexes with MEK1 and ERK2 via as yet unidentified proteins or as a result of a direct association of ERK1 with both MEK1 and ERK2.
Because intracellular hyaluronan/RHAMM interactions have been suggested to play a role in mitosis (46), the above mutant RHAMMΔ163 protein was assessed for its hyaluronan binding ability. Mutant RHAMMΔ163 retained an ability to bind to biotinylated hyaluronan consistent with evidence that Val747–Lys750 are essential for this interaction (47, 48), and peptide His715–Gln745 did not block binding of biotinylated hyaluronan to recombinant RHAMMΔ163 (data not shown). These results allowed us to clearly interpret a role of direct RHAMMΔ163/ERK1 interactions in microtubule dynamics in cells. We therefore next assessed if the D-site also mediated binding of ERK1 to RHAMM in cells. The association of ERK1 and MEK1 with RHAMMΔ163 and the ERK1 docking mutant RHAMMΔ163 (Fig. 8A) was compared by immunoprecipitation assays following transient expression of these RHAMM constructs in 10T1/2 cells (Fig. 1B) (33). ERK1/MEK1 co-associated with RHAMMΔ163 but not with the mutant RHAMMΔ163 (Fig. 9A) confirming that the D-site was necessary for ERK1/MEK1/RHAMM interactions in cells.
We then assessed if RHAMMΔ163 anchored ERK1/2 to microtubules, providing these MAPKs with access to their microtubule MAPs, which then directly modified microtubule dynamics. To begin to assess this possibility, mutant RHAMMΔ163 was expressed in H-RAS-transformed 10T1/2 cells, which exhibited high levels of microtubule-associated, active ERK1/2 (34). We expected that mutant RHAMMΔ163 would behave as a dominant negative suppressor of endogenous RHAMM proteins because RHAMM proteins dimerize and trimerize (data not shown) and because we successfully blocked the hyaluronan binding function of cell surface RHAMM with this approach (32, 33). α- and β-tubulin heterodimers were immunoprecipitated, and associated active ERK1/2 (p-ERK1/2) were detected with Western blots. Expression of mutant RHAMMΔ163 in H-RAS-transformed 10T1/2 fibroblasts resulted in loss of detectable phospho-ERK1/2 from tubulin (Fig. 9B). Total cellular levels of p-ERK1/2 were also reduced in mutant RHAMMΔ163-transfected cells, and therefore values were normalized by calculating the percent of tubulin-associated p-ERK1/2 to total cellular p-ERK in both cell lines (Fig. 9B, graph). Expression of mutant RHAMMΔ163 thus reduced the percentage of tubulin-associated p-ERK1/2 by ∼2.5-fold. We next assessed if mutant RHAMMΔ163 also affected acetylated tubulin levels. Although acetylated tubulin levels were low in H-RAS or RHAMMΔ163 10T1/2 fibroblasts, the expression of mutant RHAMMΔ163 in H-RAS 10T1/2 fibroblasts strongly increased levels of α-tubulin acetylation (Fig. 10, A and B). These results were consistent with a model in which intracellular RHAMMΔ163 functioned as an adaptor protein that bound directly to ERK1 and to tubulin but indirectly to MEK1/ERK2, thus targeting this activated kinase complex to microtubules, which phosphorylated MAPs to modify microtubule stability (Fig. 9C).
FIGURE 10.
Interactions of RHAMMΔ163 with ERK1 are required for microtubule instability in H-RAS-transformed cells. A, immunofluorescence using acetylated tubulin-specific antibodies in parental 10T1/2 cells and in 10T1/2 cells transfected with either RHAMMΔ163 or H-RAS shows that expression of these two proteins reduces microtubule stability. Expression of mutant RHAMMΔ163 in H-RAS-transformed cells blocks the effect of RAS on microtubules. Images were taken with a Zeiss confocal microscope at ×40 magnification. B, acetylated α-tubulin is quantified by densitometry analysis of Western blots. As predicted from immunofluorescence images, expression of either H-RAS or oncogenic RHAMMΔ163 significantly reduces acetylated α-tubulin levels relative to parental 10T1/2 cells, whereas conversely, expression of mutant RHAMMΔ163 restores acetylated α-tubulin to parental 10T1/2 levels. Values represent the mean ± S.E. of n = 3 assays. Statistical significance was assessed using a Student's t test, and statistically significant results (p < 0.01) are marked by an asterisk.
DISCUSSION
Our data suggest that RHAMM proteins control the structure of interphase and mitotic spindle microtubules and that these effects are driven by MEK1/ERK1/2 kinase activity. Previous reports had established an involvement of ERK1/2 in interphase microtubule dynamics resulting from their ability to phosphorylate both microtubule-stabilizing and -destabilizing proteins such as MAP and stathmin (49, 50). Our results additionally and unexpectedly reveal a role for MEK1 in restricting multi-pole mitotic spindles and promoting normal cytokinesis during mitosis. Evidence presented in this study further suggests that RHAMM/MEK1-ERK1/2 complexes affect microtubule function by promoting their dynamic instability. We therefore propose that RHAMM targets and anchors MEK1/ERK1/2 to tubulin, where these MAPKs phosphorylate the tubulin-associated proteins that regulate microtubule dynamics (5). Because the dynamic nature of microtubules has been linked to functions associated with cancer progression, including cell cycle progression and motility/invasion, our results raise the possibility that microtubules are an important oncogenic target of transforming RHAMM protein forms such as RHAMMΔ163.
The ERK1/2 MAPKs decorate both interphase microtubules and poles of mitotic spindles (50–53) and modify interphase microtubule stability (34). Although ERK1/2 kinase activity is clearly required for progression through G1/S, the direct versus indirect role of these kinases in somatic cell mitosis (G2/M) is still controversial (40, 41, 51). On the one hand, proteomic analyses have identified G2/M targets for ERK1/2 kinases (43), and blocking MEK1 with kinase inhibitors can result in aberrant mitotic spindles and a G2/M block (50, 51, 53). On the other hand, acute blocking of MEK1 activity during mitosis to prevent the direct substrate effects of this kinase pathway resulted in very minor consequences to mitosis and in particular did not influence mitotic spindle integrity of treated cells (41). The authors of this last study (41) concluded that the MEK1/ERK1/2 kinase pathway controls expression of genes necessary for progression through G2/M (e.g. cdc25C (42) and cyclinB1/cdc-2 (54)) but does not play a major role in normal G2/M by directly phosphorylating substrates. Although RHAMM may affect events in mitosis by MEK1/ERK1/2-regulated gene expression, it also appears to have direct effects on mitotic spindles because its addition to Xenopus egg extracts controls mitotic spindle pole formation and number (28). Further studies will be required to dissect the roles of direct versus indirect effects of RHAMM-MEK1-ERK1/2 complexes in mitotic spindle integrity of somatic cells.
Mitotic spindle formation is driven by multiple, cooperative microtubule nucleation and capture sites. Centrosomes play a dominant role in microtubule capture in somatic cells but are absent from germ cells and plant cells. Cells lacking centrosomes form mitotic spindles in a chromatin-dependent manner, a process that requires formation of Ran-GTP gradients (36, 55, 56). However, Ran-GTP gradients are also thought to provide kinetic stimulus but not the driving force for mitotic spindle formation in somatic cells that contain centrosomes (55). Intracellular RHAMM proteins have, to date, been most strongly implicated in Ran-dependent spindle assembly (28). Intriguingly, Ran, like RHAMM, is overexpressed in human cancers in vivo, and a number of human cancer cell lines exhibit dependence on Ran-GTP for successful mitosis. Silencing Ran expression in tumor cells results in aberrant mitotic spindle formation and apoptosis, whereas mitosis and survival of normal cell lines are largely unaffected (57, 58). Therefore, Ran-directed mitosis may predominate in diseased and/or stressed tissues, and RHAMM may also participate in spindle formation under these conditions. This possibility is consistent with evidence that RHAMM expression is primarily limited to tissue injury and neoplasia, that it associates with TPX2, a spindle pole protein required for Ran-driven mitosis (24), and that Ran-directed mitosis requires several ERK1/2 substrates, including Survivin (57) and Ran-binding protein (59–61).
The physiological and pathological processes that require RHAMM for cell division in vivo are understudied. RHAMM−/− mice are fertile and adults do not have obvious defects that can be associated with aberrant cell proliferation during embryogenesis or adult homeostasis. Loss of RHAMM reduces desmoid tumor initiation and invasion in a mouse model of tumor susceptibility, but the consequences of RHAMM loss on tumor cell division was evident only when cell-cell contact was limited in culture (62). Furthermore, although cell division was not the major focus of the study, differences in mesenchymal cell proliferation during excisional skin wound repair of RHAMM−/− versus wild type siblings were not observed (22). Thus, a major challenge for future studies will be to define the conditions under which RHAMM plays a role in mitosis in vivo.
In this study, RHAMM loss resulted in a high percentage of multi-pole spindles in mitotic cells. These results are consistent with a previous study showing that microinjection of function-blocking RHAMM antibodies also promoted multi-pole spindles (24). However, an in vitro study utilizing Xenopus egg or HeLa cell extracts showed that excess carboxyl-terminal RHAMM protein fragments promoted multiple spindle poles, whereas anti-RHAMM antibodies focused spindle poles in Ran-driven spindle formation. These effects depended upon the presence of BRCA1-BARD1 complexes, which were proposed to block the pole-stimulating function of RHAMM protein (28). This apparent discrepancy (28) with both our present results and those of Maxwell et al. (24) predicts that the mitotic functions of RHAMM are complex and may depend upon cell background, RHAMM protein levels, and possibly RHAMM isoform expression. For example, our results showing that RHAMM controls several apparently mechanistically distinct processes during mitosis is consistent with functional complexity. Thus, RHAMM loss affects not only spindle integrity but also chromosome segregation and cytokinesis, whereas the effects of RHAMM on spindle integrity and cytokinesis are mediated by MEK1, chromosome segregation appears to be mediated through other mechanisms.
In conclusion, we show that RHAMM associates with both interphase and mitotic spindle microtubules by directly binding to α- and β-tubulin through a highly conserved leucine zipper in its carboxyl terminus. This interaction promotes dynamic instability of interphase microtubules and is associated with mitotic spindle defects that can also arise from altered microtubule stability. These RHAMM-mediated effects require MEK1/ERK1/2 activity. Because RHAMM binds directly to both α/β-tubulin and ERK1, and complexes with MEK1/ERK2, we propose that intracellular carboxyl-terminal fragments of RHAMM perform scaffolding functions linking active MEK1/ERK1/2 to their microtubule substrates.
Supplementary Material
This work was supported, in whole or in part, by National Institutes of Health Grant 5R0119092 from NCI (to J. B. M. and E. A. T.). This work was also supported by a grant from the Cancer Research Society, Montreal, Canada (to E. A. T.), and by the Canadian Breast Cancer Society (partial salary to E. A. T.).

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1–6.
- MAP
- microtubule-associated protein
- MEF
- mouse embryo fibroblast.
REFERENCES
- 1.van der Vaart B., Akhmanova A., Straube A. (2009) Biochem. Soc. Trans. 37, 1007–1013 [DOI] [PubMed] [Google Scholar]
- 2.Alberti C. (2009) Eur. Rev. Med. Pharmacol. Sci. 13, 13–21 [PubMed] [Google Scholar]
- 3.Arce C. A., Casale C. H., Barra H. S. (2008) FEBS J. 275, 4664–4674 [DOI] [PubMed] [Google Scholar]
- 4.Holmfeldt P., Sellin M. E., Gullberg M. (2009) Cell. Mol. Life Sci. 66, 3263–3276 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Hammond J. W., Huang C. F., Kaech S., Jacobson C., Banker G., Verhey K. J. (2009) Mol. Biol. Cell 21, 572–583 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Verhey K. J., Gaertig J. (2007) Cell Cycle 6, 2152–2160 [DOI] [PubMed] [Google Scholar]
- 7.Kotwaliwale C., Biggins S. (2006) Cell 127, 1105–1108 [DOI] [PubMed] [Google Scholar]
- 8.Crasta K., Lim H. H., Zhang T., Nirantar S., Surana U. (2008) Cell Cycle 7, 2960–2966 [DOI] [PubMed] [Google Scholar]
- 9.Tillement V., Remy M. H., Raynaud-Messina B., Mazzolini L., Haren L., Merdes A. (2009) Biol. Cell 101, 1–11 [DOI] [PubMed] [Google Scholar]
- 10.Maiato H., DeLuca J., Salmon E. D., Earnshaw W. C. (2004) J. Cell Sci. 117, 5461–5477 [DOI] [PubMed] [Google Scholar]
- 11.Bedard P. L., Di Leo A., Piccart-Gebhart M. J. (2010) Nat. Rev. Clin. Oncol. 7, 22–36 [DOI] [PubMed] [Google Scholar]
- 12.Perez E. A. (2009) Mol. Cancer Ther. 8, 2086–2095 [DOI] [PubMed] [Google Scholar]
- 13.Schwartz J. (2009) Am. J. Health Syst. Pharm. 66, S3–8 [DOI] [PubMed] [Google Scholar]
- 14.Greiner J., Bullinger L., Guinn B. A., Döhner H., Schmitt M. (2008) Clin. Cancer Res. 14, 7161–7166 [DOI] [PubMed] [Google Scholar]
- 15.Maxwell C. A., McCarthy J., Turley E. (2008) J. Cell Sci. 121, 925–932 [DOI] [PubMed] [Google Scholar]
- 16.Giannopoulos K., Schmitt M. (2006) Leuk. Lymphoma 47, 2028–2036 [DOI] [PubMed] [Google Scholar]
- 17.Wang C., Thor A. D., Moore D. H., 2nd, Zhao Y., Kerschmann R., Stern R., Watson P. H., Turley E. A. (1998) Clin. Cancer Res. 4, 567–576 [PubMed] [Google Scholar]
- 18.Pujana M. A., Han J. D., Starita L. M., Stevens K. N., Tewari M., Ahn J. S., Rennert G., Moreno V., Kirchhoff T., Gold B., Assmann V., Elshamy W. M., Rual J. F., Levine D., Rozek L. S., Gelman R. S., Gunsalus K. C., Greenberg R. A., Sobhian B., Bertin N., Venkatesan K., Ayivi-Guedehoussou N., Solé X., Hernández P., Lázaro C., Nathanson K. L., Weber B. L., Cusick M. E., Hill D. E., Offit K., Livingston D. M., Gruber S. B., Parvin J. D., Vidal M. (2007) Nat. Genet. 39, 1338–1349 [DOI] [PubMed] [Google Scholar]
- 19.Kalmyrzaev B., Pharoah P. D., Easton D. F., Ponder B. A., Dunning A. M. (2008) Cancer Epidemiol. Biomarkers Prev. 17, 3618–3620 [DOI] [PubMed] [Google Scholar]
- 20.Schmitt M., Schmitt A., Rojewski M. T., Chen J., Giannopoulos K., Fei F., Yu Y., Götz M., Heyduk M., Ritter G., Speiser D. E., Gnjatic S., Guillaume P., Ringhoffer M., Schlenk R. F., Liebisch P., Bunjes D., Shiku H., Dohner H., Greiner J. (2008) Blood 111, 1357–1365 [DOI] [PubMed] [Google Scholar]
- 21.Slevin M., Krupinski J., Gaffney J., Matou S., West D., Delisser H., Savani R. C., Kumar S. (2007) Matrix Biol. 26, 58–68 [DOI] [PubMed] [Google Scholar]
- 22.Tolg C., Hamilton S. R., Nakrieko K. A., Kooshesh F., Walton P., McCarthy J. B., Bissell M. J., Turley E. A. (2006) J. Cell Biol. 175, 1017–1028 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Assmann V., Jenkinson D., Marshall J. F., Hart I. R. (1999) J. Cell Sci. 112, 3943–3954 [DOI] [PubMed] [Google Scholar]
- 24.Maxwell C. A., Keats J. J., Crainie M., Sun X., Yen T., Shibuya E., Hendzel M., Chan G., Pilarski L. M. (2003) Mol. Biol. Cell 14, 2262–2276 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Lynn B. D., Li X., Cattini P. A., Turley E. A., Nagy J. I. (2001) J. Comp. Neurol. 439, 315–330 [DOI] [PubMed] [Google Scholar]
- 26.Radisky D. C., Stallings-Mann M., Hirai Y., Bissell M. J. (2009) Nat. Rev. Mol. Cell Biol. 10, 228–234 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Hamilton S. R., Fard S. F., Paiwand F. F., Tolg C., Veiseh M., Wang C., McCarthy J. B., Bissell M. J., Koropatnick J., Turley E. A. (2007) J. Biol. Chem. 282, 16667–16680 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Joukov V., Groen A. C., Prokhorova T., Gerson R., White E., Rodriguez A., Walter J. C., Livingston D. M. (2006) Cell 127, 539–552 [DOI] [PubMed] [Google Scholar]
- 29.Groen A. C., Cameron L. A., Coughlin M., Miyamoto D. T., Mitchison T. J., Ohi R. (2004) Curr. Biol. 14, 1801–1811 [DOI] [PubMed] [Google Scholar]
- 30.Maxwell C. A., Keats J. J., Belch A. R., Pilarski L. M., Reiman T. (2005) Cancer Res. 65, 850–860 [PubMed] [Google Scholar]
- 31.Fang Z., Takizawa N., Wilson K. A., Smith T. C., Delprato A., Davidson M. W., Lambright D. G., Luna E. J. (2010) Traffic 11, 782–799 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Hall C. L., Yang B., Yang X., Zhang S., Turley M., Samuel S., Lange L. A., Wang C., Curpen G. D., Savani R. C., Greenberg A. H., Turley E. A. (1995) Cell 82, 19–26 [DOI] [PubMed] [Google Scholar]
- 33.Zhang S., Chang M. C., Zylka D., Turley S., Harrison R., Turley E. A. (1998) J. Biol. Chem. 273, 11342–11348 [DOI] [PubMed] [Google Scholar]
- 34.Harrison R. E., Turley E. A. (2001) Neoplasia 3, 385–394 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Mohan R., Panda D. (2008) Cancer Res. 68, 6181–6189 [DOI] [PubMed] [Google Scholar]
- 36.Karsenti E., Vernos I. (2001) Science 294, 543–547 [DOI] [PubMed] [Google Scholar]
- 37.Walczak C. E., Cai S., Khodjakov A. (2010) Nat. Rev. Mol. Cell Biol. 11, 91–102 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.von Dassow G. (2009) Trends Cell Biol. 19, 165–173 [DOI] [PubMed] [Google Scholar]
- 39.Zhou F. Q., Snider W. D. (2006) Philos. Trans. R. Soc. Lond. B Biol. Sci. 361, 1575–1592 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Matkovic K., Lukinovic-Skudar V., Banfic H., Visnjic D. (2009) Int. J. Hematol. 89, 159–166 [DOI] [PubMed] [Google Scholar]
- 41.Shinohara M., Mikhailov A. V., Aguirre-Ghiso J. A., Rieder C. L. (2006) Mol. Biol. Cell 17, 5227–5240 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Wang R., He G., Nelman-Gonzalez M., Ashorn C. L., Gallick G. E., Stukenberg P. T., Kirschner M. W., Kuang J. (2007) Cell 128, 1119–1132 [DOI] [PubMed] [Google Scholar]
- 43.Roberts E. C., Hammond K., Traish A. M., Resing K. A., Ahn N. G. (2006) Proteomics 6, 4541–4553 [DOI] [PubMed] [Google Scholar]
- 44.Ramos J. W. (2008) Int. J. Biochem. Cell Biol. 40, 2707–2719 [DOI] [PubMed] [Google Scholar]
- 45.Bardwell L. (2006) Biochem. Soc. Trans. 34, 837–841 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Evanko S. P., Parks W. T., Wight T. N. (2004) J. Histochem. Cytochem. 52, 1525–1535 [DOI] [PubMed] [Google Scholar]
- 47.Ziebell M. R., Prestwich G. D. (2004) J. Comput. Aided Mol. Des. 18, 597–614 [DOI] [PubMed] [Google Scholar]
- 48.Yang B., Yang B. L., Savani R. C., Turley E. A. (1994) EMBO J. 13, 286–296 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Richter-Landsberg C. (2008) J. Mol. Neurosci. 35, 55–63 [DOI] [PubMed] [Google Scholar]
- 50.Sturgill T. W. (2008) Biochem. Biophys. Res. Commun. 371, 1–4 [DOI] [PubMed] [Google Scholar]
- 51.Chambard J. C., Lefloch R., Pouysségur J., Lenormand P. (2007) Biochim. Biophys. Acta 1773, 1299–1310 [DOI] [PubMed] [Google Scholar]
- 52.Lefloch R., Pouysségur J., Lenormand P. (2009) Cell Cycle 8, 705–711 [DOI] [PubMed] [Google Scholar]
- 53.Mebratu Y., Tesfaigzi Y. (2009) Cell Cycle 8, 1168–1175 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Dumesic P. A., Scholl F. A., Barragan D. I., Khavari P. A. (2009) J. Cell Biol. 185, 409–422 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Clarke P. R., Zhang C. (2008) Nat. Rev. Mol. Cell Biol. 9, 464–477 [DOI] [PubMed] [Google Scholar]
- 56.O'Connell C. B., Khodjakov A. L. (2007) J. Cell Sci. 120, 1717–1722 [DOI] [PubMed] [Google Scholar]
- 57.Xia F., Canovas P. M., Guadagno T. M., Altieri D. C. (2008) Mol. Cell. Biol. 28, 5299–5311 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Xia F., Lee C. W., Altieri D. C. (2008) Cancer Res. 68, 1826–1833 [DOI] [PubMed] [Google Scholar]
- 59.Klein U. R., Haindl M., Nigg E. A., Muller S. (2009) Mol. Biol. Cell 20, 410–418 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Lewis T. S., Hunt J. B., Aveline L. D., Jonscher K. R., Louie D. F., Yeh J. M., Nahreini T. S., Resing K. A., Ahn N. G. (2000) Mol. Cell 6, 1343–1354 [DOI] [PubMed] [Google Scholar]
- 61.Kim Y. H., Lee D. H., Jeong J. H., Guo Z. S., Lee Y. J. (2008) Biochem. Pharmacol. 75, 1946–1958 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Tolg C., Poon R., Fodde R., Turley E. A., Alman B. A. (2003) Oncogene 22, 6873–6882 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.










